NeonMind Announces Organizational Changes
May 30, 2022
May 30, 2022 6:00pm EDT Oakville, Ontario – May 30, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF0) (“NeonMind” or the “Company”) announced today
Clear Minds,
Bright Future
Advancing Psychedelic Science to Tackle Obesity, Mental Health, and Wellness
NeonMind Biosciences Inc., is an integrated psychedelic drug development and wellness company focused on the therapeutic uses of psychedelics to address public health needs including obesity, weight management and mental health. At NeonMind Biosciences, we believe in “mind over matter” with the ultimate goal of supporting human health through our psychedelic drug development program and NeonMind-branded specialty mental health clinics.
Harnessing Psychedelic Medicine Through Evidence and Science
In our pharmaceutical division, we are developing the first and only novel psilocybin-based drug candidates targeting obesity, a global health issue and one of the leading causes of death. Integral to the adoption of psychedelic medicine is the deployment of medical treatment services. NeonMind has established a medical services division which will be launching specialty mental health clinics in Canada that incorporate innovative, evidence-backed validated interventional psychiatry treatments for mood and anxiety disorders, a leading cause of disability in our society. Our goal is to help patients with weight management and mental health issues.
Our Dual Approach to Psychedelic Medicine
We are advancing psychedelic medicine and therapeutic treatments to improve bodies and minds through our two operating divisions.
Pharmaceutical Division
Targeting Obesity with Revolutionary Psychedelic Compounds
NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional drug candidate, NEO-002, which employs low-dose psilocybin to control appetite. In addition, the Company has extensive U.S. and international patent applications pending which cover a wide spectrum of weight management conditions.
Medical Services Division
Enhancing Access to Specialized Interventional Psychiatry Treatments through NeonMind Clinics
Our medical services division is preparing to launch NeonMind-branded specialty mental health clinics across Canada, offering evidence-backed validated interventional psychiatry treatments tailored to local market needs. The Company has built a leading scientific advisory board, globally renowned for their expertise in practicing interventional psychiatry to treat mood and anxiety disorders. A medical services platform entrenched in the growing psychedelic sector, by improving access to validated treatments and incorporating the promising pipeline of psychedelic treatments as they are approved.
NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health Clinic
Apr 21, 2022
April 21, 2021 8:00am EDT Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE
NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic
Apr 19, 2022
April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE /
Email Alerts
Stay informed and receive company updates straight to your inbox.
English